PE: How are global regulatory agencies adjusting their policies for biosimilars? Woollett: The clear leaders in the space of ...

With the first 15 CNPVs now awarded, we can begin to see a clear pattern: the winners weren’t just those with breakthrough science, but those with operational models ready for an accelerated, ...

TrumpRx lowers drug prices but doesn't address diagnosis and care access barriers, limiting its impact on patient outcomes. Pharma must develop DTP programs integrating education, testing, and ...

In today’s Pharmaceutical Executive Daily, new analysis outlines what it may truly cost to fix the biopharma ecosystem, the ...

OTR Therapeutics and Zealand Pharma collaborate to develop novel metabolic disease treatments, with a potential deal value of ...

The Trump administration has taken steps to strengthen domestic manufacturing across all industries since coming into office ...

Lilly’s first Phase III results for retatrutide show unprecedented weight loss and marked reductions in osteoarthritis pain, ...

M&A in biopharma is shaped by policy uncertainties, tariffs, and potential marketing rule changes, influencing strategic ...

DTC prescription drug models are reshaping the pharma industry by altering pricing dynamics and enhancing patient access, ...

While pharmaceutical pricing has been a controversial topic for many years, a new spotlight was shone on it over the past 12 months.